Inactive Instrument

Kanabo Group Plc Stock London S.E.

Equities

SOP

GB00BYQCS703

Pharmaceuticals

Financials

Sales 2021 73K 91.19K 125K Sales 2022 603K 753K 1.03M Capitalization 8.04M 10.04M 13.72M
Net income 2021 -4M -5M -6.83M Net income 2022 -6M -7.5M -10.25M EV / Sales 2021 648 x
Net cash position 2021 4.5M 5.62M 7.68M Net cash position 2022 3.01M 3.76M 5.14M EV / Sales 2022 8.33 x
P/E ratio 2021
-9.98 x
P/E ratio 2022
-1.15 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 50.93%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 46 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 62 23-05-08
Director/Board Member 73 21-06-27
Director/Board Member 51 23-05-03
More insiders
Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.
More about the company